Patents by Inventor Andreas Koblet

Andreas Koblet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLIDINE DERIVATIVES
    Publication number: 20110144081
    Abstract: The present invention relates to compounds of formula wherein R1, R2, R3, R4, Z, and n are as defined herein or to a pharmaceutically active salt thereof. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
    Type: Application
    Filed: December 7, 2010
    Publication date: June 16, 2011
    Inventors: Henner Knust, Andreas Koblet, Matthias Nettekoven, Hasane Ratni, Claus Riemer, Walter Vifian
  • Aryl-isoxazolo-4-yl-oxadiazole derivatives
    Patent number: 7956074
    Abstract: The present invention is concerned with isoxazol-4-yl-oxadiazole derivatives of formula wherein R1, R2, and R3, are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. This class of compounds has high affinity and selectivity for GABA A ?5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: June 7, 2011
    Assignee: Hoffman-La Roche Inc.
    Inventors: Bernd Buettelmann, Bo Han, Henner Knust, Andreas Koblet, Andrew Thomas
  • Dual NK1/NK3 receptor antagonists
    Patent number: 7939533
    Abstract: The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula wherein the substituents are as described herein or a pharmaceutically active acid-addition salt thereof. In particular, the invention provides methods for treating both positive and negative symptoms of schizophrenia through dual inhibition of NK1 and NK3 receptors. The invention also provides novel compounds with formula I and methods for preparing compounds of the invention.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: May 10, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Torsten Hoffmann, Andreas Koblet, Jens-Uwe Peters, Patrick Schnider, Andrew Sleight, Heinz Stadler
  • PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS
    Publication number: 20090312327
    Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, Ar and n are as defined herein and pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers or tautomeric forms thereof. The compounds can be used for the treatment of depression, anxiety or schizophrenia.
    Type: Application
    Filed: June 11, 2009
    Publication date: December 17, 2009
    Inventors: Caterina Bissantz, Philippe Jablonski, Henner Knust, Andreas Koblet, Anja Limberg, Matthias Nettekoven, Hasane Ratni, Claus Riemer
  • ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES
    Publication number: 20090197875
    Abstract: The present invention is concerned with isoxazol-4-yl-oxadiazole derivatives of formula wherein R1, R2, and R3, are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. This class of compounds has high affinity and selectivity for GABA A ?5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    Type: Application
    Filed: April 13, 2009
    Publication date: August 6, 2009
    Inventors: Bernd Buettelmann, Bo Han, Henner Knust, Andreas Koblet, Andrew Thomas
  • Aryl-isoxazolo-4-yl-oxadiazole derivatives
    Patent number: 7541372
    Abstract: The present invention is concerned with isoxazol-4-yl-oxadiazole derivatives of formula wherein R1, R2, and R3, are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. This class of compounds has high affinity and selectivity for GABA A ?5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: June 2, 2009
    Assignee: Hoffman-La Roche Inc.
    Inventors: Bernd Buettelmann, Bo Han, Henner Knust, Andreas Koblet, Andrew Thomas
  • DUAL NK1/NK3 RECEPTOR ANTAGONISTS
    Publication number: 20090137806
    Abstract: The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula wherein the substituents are as described herein or a pharmaceutically active acid-addition salt thereof. In particular, the invention provides methods for treating both positive and negative symptoms of schizophrenia through dual inhibition of NK1 and NK3 receptors. The invention also provides novel compounds with formula I and methods for preparing compounds of the invention.
    Type: Application
    Filed: January 29, 2009
    Publication date: May 28, 2009
    Inventors: Torsten Hoffmann, Andreas Koblet, Jens-Uwe Peters, Patrick Schnider, Andrew Sleight, Heinz Stadler
  • Aryl-isoxazolo-4-yl-oxadiazole derivatives
    Publication number: 20070161686
    Abstract: The present invention is concerned with isoxazol-4-yl-oxadiazole derivatives of formula wherein R1, R2, and R3, are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. This class of compounds has high affinity and selectivity for GABA A ?5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    Type: Application
    Filed: December 15, 2006
    Publication date: July 12, 2007
    Inventors: Bernd Buettelmann, Bo Han, Henner Knust, Andreas Koblet, Andrew Thomas
  • Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
    Publication number: 20070129419
    Abstract: The present invention relates to cis-derivatives of formula wherein R1, R2, and R3 are as defined herein and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors). By virtue of their efficacy as SERT inhibitors, the compounds of the present invention are particularly useful for the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and/or in the treatment of anxiety.
    Type: Application
    Filed: November 22, 2006
    Publication date: June 7, 2007
    Inventors: Christophe Grundschober, Torsten Hoffmann, Andreas Koblet, Patrick Schnider
  • NK-1 receptor antagonists
    Patent number: 7211579
    Abstract: The present invention relates to compounds of formula I wherein R is methyl; and R1 is 4-methyl-4-oxy-piperazin-1-yl; or R is CH2OH and R1 is 4-methyl-piperazin-1-yl or is 4-methyl-4-oxy-piperazin-1-yl; and to pharmaceutically acceptable acid addition salts thereof for the treatment of NK-1 receptor related diseases, for example depression, Parkinson's disease, Alzheimer's disease, anxiety, emesis, and pain.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: May 1, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christoph Funk, Torsten Hoffmann, Andreas Koblet
  • NK-1 receptor antagonists
    Publication number: 20060217393
    Abstract: The present invention relates to compounds of formula I wherein R is methyl; and R1 is 4-methyl-4-oxy-piperazin-1-yl; or R is CH2OH and R1 is 4-methyl-piperazin-1-yl or is 4-methyl-4-oxy-piperazin-1-yl; and to pharmaceutically acceptable acid addition salts thereof for the treatment of NK-1 receptor related diseases, for example depression, Parkinson's disease, Alzheimer's disease, anxiety, emesis, and pain.
    Type: Application
    Filed: March 15, 2006
    Publication date: September 28, 2006
    Inventors: Christoph Funk, Torsten Hoffmann, Andreas Koblet
  • Dual NK1/NK3 receptor antagonists
    Publication number: 20050090533
    Abstract: The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula wherein the substituents are as described herein or a pharmaceutically active acid-addition salt thereof. In particular, the invention provides methods for treating both positive and negative symptoms of schizophrenia through dual inhibition of NK1 and NK3 receptors. The invention also provides novel compounds with formula I and methods for preparing compounds of the invention.
    Type: Application
    Filed: July 2, 2004
    Publication date: April 28, 2005
    Inventors: Torsten Hoffmann, Andreas Koblet, Jens-Uwe Peters, Patrick Schnider, Andrew Sleight, Heinz Stadler